TY - JOUR
T1 - CheckAP
T2 - Prevalence of Psoriatic Arthritis (PsA) and performance evaluation of the EARP Questionnaire in the population of Portuguese patients with Psoriasis followed in a dermatology setting
AU - Henriques, Ana Rita
AU - Pimentel-Santos, Fernando
AU - Teles de Sousa, João
AU - Silva, Leandro
AU - Gago, Laura
AU - Santos, Mariana Emília
AU - Teodósio Chícaro, Ana
AU - Lucas Rocha, Margarida
AU - Pinheiro Torres, Rita
AU - Pimentel, Bernardo
AU - Lourenço, Maria Helena
AU - Barão Neves, Sandra
AU - Gusmão Palmeiro, Ana
AU - Barcelos, Anabela
AU - Loureiro, Manuela
AU - Silva, Susana
AU - Vieira-Sousa, Elsa
AU - Ochôa Matos, Carolina
AU - Ferro Antunes, Joana
AU - Alpalhão, Miguel
AU - Correia Amaral, Nadine
AU - Bernardo, Alexandra
AU - Magina, Sofia
AU - Seabra Rato, Maria
AU - Ponte, Pedro
AU - Meirinhos, Tiago
AU - Torres, Tiago
AU - Rodrigues, Marília
AU - Henrique, Martinha
AU - Jesus, Diogo
AU - Daniel, Alexandra
AU - Brites, Luísa
AU - Nero, Patrícia
AU - Mendes-Bastos, Pedro
AU - Pedro Valada, Maria
AU - Lopes, David
AU - Dinis de Sousa, Rute
AU - Canhão, Helena
AU - Rodrigues, Ana Maria
N1 - Publisher Copyright:
© 2024, Sociedade Portuguesa de Reumatologia. All rights reserved.
PY - 2024/10/1
Y1 - 2024/10/1
N2 - Background: The percentage of Portuguese psoriasis patients with psoriatic arthritis is unknown but musculoskeletal complaints related to PsA affect up to a third of patients. Dermatologists can identify early PsA as skin symptoms often precede joint symptoms in 80% of patients. Efficient and easy to perform screening tools are needed to help dermatologists effectively discriminate between Pso and PsA patients. The present study aims to evaluate the prevalence of PsA in Pso patients followed in Portuguese dermatology clinics. Additionally, it aims to evaluate the EARP-PT performance (validity, sensitivity, specificity) and the best cut-off point to allow an early identification of PsA potential patients.
Methods: A multicentre national, cross-sectional, observational study with two independent assessments (dermatologist and rheumatologist), was performed. A PsA case was defined by a combination of expert opinion and classification criteria for psoriatic arthritis (CASPAR). The EARP-PT questionnaire screening performance was evaluated.
Results: Pso patients (n=172) were included with a mean age of 53.8 ± 14.5 years, 53.5% were male with a mean time of diagnosis of 17.4 ± 14.9 years. The prevalence of PsA in patients with Pso in our sample was 8.70% (95% CI: 4.8-14.2). The EARP-PT questionnaire displayed good internal consistency (Cronbach’s a=0.81) and, using a validated initial cut-off point of 3, demonstrated a sensitivity of 71.4% and specificity of 40.1%.
Conclusion: The estimated prevalence of PsA in a population of Pso patients followed in Portuguese dermatology clinics, is 8.7%. The EARP-PT questionnaire appears to be a useful tool for dermatologists in the early detection of PsA.
AB - Background: The percentage of Portuguese psoriasis patients with psoriatic arthritis is unknown but musculoskeletal complaints related to PsA affect up to a third of patients. Dermatologists can identify early PsA as skin symptoms often precede joint symptoms in 80% of patients. Efficient and easy to perform screening tools are needed to help dermatologists effectively discriminate between Pso and PsA patients. The present study aims to evaluate the prevalence of PsA in Pso patients followed in Portuguese dermatology clinics. Additionally, it aims to evaluate the EARP-PT performance (validity, sensitivity, specificity) and the best cut-off point to allow an early identification of PsA potential patients.
Methods: A multicentre national, cross-sectional, observational study with two independent assessments (dermatologist and rheumatologist), was performed. A PsA case was defined by a combination of expert opinion and classification criteria for psoriatic arthritis (CASPAR). The EARP-PT questionnaire screening performance was evaluated.
Results: Pso patients (n=172) were included with a mean age of 53.8 ± 14.5 years, 53.5% were male with a mean time of diagnosis of 17.4 ± 14.9 years. The prevalence of PsA in patients with Pso in our sample was 8.70% (95% CI: 4.8-14.2). The EARP-PT questionnaire displayed good internal consistency (Cronbach’s a=0.81) and, using a validated initial cut-off point of 3, demonstrated a sensitivity of 71.4% and specificity of 40.1%.
Conclusion: The estimated prevalence of PsA in a population of Pso patients followed in Portuguese dermatology clinics, is 8.7%. The EARP-PT questionnaire appears to be a useful tool for dermatologists in the early detection of PsA.
KW - Dermatology
KW - EARP Questionnaire
KW - Psoriasis
KW - Psoriatic arthritis
KW - Rheumatology
UR - http://www.scopus.com/inward/record.url?scp=85214380258&partnerID=8YFLogxK
U2 - 10.63032/WFLZ4806
DO - 10.63032/WFLZ4806
M3 - Article
AN - SCOPUS:85214380258
SN - 2795-4552
VL - 3
SP - 258
EP - 267
JO - ARP rheumatology
JF - ARP rheumatology
IS - 4
ER -